Erasca (ERAS) has had the highest return since January 1, 2026 by a mid-cap US stock, returning 358.5%.
| ASSET | % RETURN |
|---|---|
Erasca (ERAS) | 358.49% |
AXT (AXTI) | 273.14% |
Immunitybio (IBRX) | 260.4% |
Aehr Test Systems (AEHR) | 235.06% |
Enliven Therapeutics (ELVN) | 192.39% |
Ultra Clean (UCTT) | 190.02% |
Babcock & Wilcox Enterprises (BW) | 168.31% |
Alumis (ALMS) | 135.93% |
Viavi Solutions (VIAV) | 131.52% |
Day One Biopharmaceuticals (DAWN) | 131.11% |
Tango Therapeutics (TNGX) | 125.42% |
Fastly, Inc Class A Common Stock (FSLY) | 123.33% |
Dianthus Therapeutics (DNTH) | 118.37% |
FormFactor (FORM) | 114% |
Powell Industries (POWL) | 113.94% |
Amprius Technologies (AMPX) | 103.79% |
Almonty Industries Inc Common Shares (ALM) | 103.64% |
Veradermics (MANE) | 102.35% |
Aura Minerals Inc Common Shares (AUGO) | 100.97% |
Oruka Therapeutics (ORKA) | 96.57% |
Iridium Communications (IRDM) | 96.39% |
Sasol (SSL) | 96.15% |
Valaris (VAL) | 93.25% |
Chemours (CC) | 91.01% |
Argan (AGX) | 90.69% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
